Search clinical trials for: Surufatinib Serplulimab Albumin-paclitaxel Gemcitabine

Total 1548 results

Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
Qilu Hospital of Shandong University

Recruiting

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Hutchmed

Completed

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Lymphoma | Osteosarcoma | Solid Tumor | Ewing Sarcoma | Rhabdomyosarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Muhammad Furqan
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Small Cell Lung Cancer (SCLC)

United States
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Jinling Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant Therapy

China
Trishula Therapeutics, Inc.
AbbVie

Recruiting

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Pancreatic Cancer

United States, Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma

United States
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Spanish Cooperative Group for the Treatment of...

Completed

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (SEQUENCE)

Metastatic Pancreatic Adenocarcinoma

Spain
Tianjin Medical University Cancer Institute and...

Recruiting

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

Pancreatic Cancer

China
Memorial Sloan Kettering Cancer Center
Celgene Corporation; Miami Cancer Institute

Completed

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Lung Cancer | Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

United States
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer (NAPGAP)

Advanced Pancreatic Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Resectable Pancreatic Carcinoma | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and v7

United States
Fudan University

Unknown

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Fudan University

Not yet recruiting

Phase II Study of Sufantinib Combined With AG Versus AG First-line in the Treatment of LAPC or mPC

Pancreatic Neoplasms

China
RenJi Hospital

Recruiting

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV

China
Roswell Park Cancer Institute
National Cancer Institute (NCI); Novartis

Withdrawn

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
AIO-Studien-gGmbH
Celgene Corporation; ClinAssess GmbH

Completed

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (ALPACA)

Adenocarcinoma of the Pancreas | Metastatic Pancreatic Cancer

Germany
Helse Stavanger HF

Unknown

Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients (PACT-ACT-v6)

Metastatic Pancreatic Cancer

Norway
Fudan University

Recruiting

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer (PTCA199-3)

Metastatic Pancreatic Adenocarcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Pancreas Cancer

United States
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NabucCO)

Metastatic Pancreatic Cancer

Italy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chinese PLA General Hospital

Completed

Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract

Carcinoma, Transitional Cell

China
University of California, San Francisco
Celgene Corporation

Completed

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

Adenocarcinoma | Pancreatic Neoplasms | Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Washington University School of Medicine
National Cancer Institute (NCI); BioMed Valley Discoveries, Inc

Terminated

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Pancreatic Cancer

China
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan

Search clinical trials for: Surufatinib Serplulimab Albumin-paclitaxel Gemcitabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations